Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 7OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Breast Neoplasms 272Carcinoma, Non-Small-Cell Lung 195Prostatic Neoplasms 171Stomach Neoplasms 100Lung Neoplasms 93Squamous Cell Carcinoma of Head and Neck 74Head and Neck Neoplasms 69Esophageal Neoplasms 56Neoplasms 47Neoplasm Metastasis 36Pancreatic Neoplasms 31Nasopharyngeal Carcinoma 30Ovarian Neoplasms 27Sarcoma 26Urinary Bladder Neoplasms 25Triple Negative Breast Neoplasms 20Adenocarcinoma 19Carcinoma, Squamous Cell 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Carcinoma, Ovarian Epithelial 15Unspecified Adult Solid Tumor, Protocol Specific 13Carcinoma, Transitional Cell 13Breast Neoplasms, Male 13Adenocarcinoma of Lung 12Salivary Gland Neoplasms 11Laryngeal Neoplasms 11Small Cell Lung Carcinoma 10Inflammatory Breast Neoplasms 10Uterine Cervical Neoplasms 9

Interventions

Fluorodeoxyglucose F18 7Irinotecan 4Fluorouracil 4Cyclophosphamide 4Bevacizumab 4toripalimab 3pembrolizumab 3olaparib 3Radiosurgery 3Cisplatin 3Capecitabine 3vistusertib 2tislelizumab 2spartalizumab 2fludarabine 2atezolizumab 2apatinib 2Temozolomide 2Technetium 2Specimen Handling 2Sirolimus 2Radiotherapy 2Proton Therapy 2Paclitaxel 2Leucovorin 2Letrozole 2Hydroxychloroquine 2Everolimus 2Drug Therapy 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Solid Tumor × Docetaxel × Clear all
NCT04360317 2020-04-24

Safety of the Combination of SH003 and Docetaxel in Patients With Solid Cancer

Kyunghee University Medical Center

Phase 1 Unknown
9 enrolled
Other solid neoplasm

Solid Tumor

NCT00251407 2012-08-09

Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies

Dana-Farber Cancer Institute

Phase 1 Completed
46 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡